Pericarditis secondary to COVID-19 infection in a kidney transplant recipient

Pérez, Jose Javier Navarro; Girbal, Lucia Aubert; Caravaca-Fontán, Fernando; Polanco, Natalia; Prieto, Ángel Sevillano; Andrés, Amado

doi:10.1016/j.nefroe.2021.07.003

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a full-text assessment of the 53 remaining articles, 20 were excluded because of other population (17), incomplete data (2), and review (1). Finally, 33 articles (32 case reports and 1 case series) 7–39 were selected (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

“…Other used drugs were corticosteroids (n ¼ 8), empirical antibiotics (n ¼ 7), immunoglobulin (n ¼ 2), and remdesivir (n ¼ 2). In six patients, 20,26,28,30,34,36 corticosteroids were administered as part of the COVID-19 treatment, while in the remaining two patients, 16,18 it was given for myopericarditis. Thirteen patients (38%) were treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and 18 patients (53%) with colchicine.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pericarditis in patients with COVID-19: a systematic review

Diaz‐Arocutipa

Saucedo-Chinchay

Imazio

2021

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Aims We performed a systematic review to summarize the clinical features, diagnostic methods, treatment, and outcomes of coronavirus disease 2019 (COVID-19) patients with pericarditis. Methods We searched electronic databases from inception to 17 December 2020. Studies that reported clinical data on patients with COVID-19 and pericarditis were included. Descriptive statistics were used for categorical and continuous variables [mean ± standard deviation or median (interquartile range)]. As an exploratory analysis, differences between patients with acute pericarditis and myopericarditis were compared. Results A total of 33 studies (32 case reports and 1 case series) involving 34 patients were included. The mean age was 51.6 ± 19.5 years and 62% of patients were men. Sixty-two percentage of patients were diagnosed with myopericarditis. The most frequent electrocardiographic pattern (56%) was diffuse ST-elevation and PR depression. Pericardial effusion and cardiac tamponade were reported in 76 and 35% of cases, respectively. The median values of C-reactive protein [77 mg/dl (12–177)] and white blood cells [12 335 cells/μl (5625–16 500)] were above the normal range. Thirty-eight percent and 53% of patients were treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine, respectively. These drugs were more frequently used in patients with acute pericarditis compared with myopericarditis. The in-hospital mortality was 6% without a significant difference between both groups. Conclusion Our review shows that COVID-19 patients with pericarditis had similar clinical features to other viral cardiotropic infections. However, NSAIDs and colchicine were used in half or less of the cases. Overall, the short-term prognosis was good across groups.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Pericarditis in patients with COVID-19: a systematic review

Diaz‐Arocutipa

Saucedo-Chinchay

Imazio

2021

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

A Systematic Review of COVID-19 and Pericarditis

Kariyanna¹,

Ahmed²,

Sutarjono³

et al. 2022

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China in December 2019. Since then, the disease has spread globally, leading to the ongoing pandemic. It can cause severe respiratory illness; however, many cases of pericarditis have also been reported. This systematic review aims to recognize the clinical features of pericarditis and myopericarditis in COVID-19 patients.Google Scholar, Medline/PubMed, CINAHL, Cochrane Central, and Web of Science databases were searched for studies reporting "Coronavirus" or "COVID" and "Peri-myocarditis," "heart," or "retrospective." Case reports and retrospective studies published from May 2020 to February 2021 were reviewed.In total, 33 studies on pericarditis, myopericarditis, and pericardial infusion were included in this review. COVID-19 pericarditis affected adult patients at any age. The incidence is more common in males, with a male-to-female ratio of 2:1. Chest pain (60%), fever (51%), and shortness of breath (51%) were the most reported symptoms, followed by cough (39%), fatigue (15%), myalgia (12%), and diarrhea (12%). Laboratory tests revealed leukocytosis with neutrophil predominance, elevated D-dimer, erythrocyte rate, and Creactive protein. Cardiac markers including troponin-1, troponin-T, and brain natriuretic peptide were elevated in most cases. Radiographic imaging of the chest were mostly normal, and only 31% of chest X-rays showed cardiomegaly and or bilateral infiltration. Electrocardiography (ECG) demonstrated normal sinus rhythm with around 59% ST elevation and rarely PR depression or T wave inversion, while the predominant echocardiographic feature was pericardial effusion. Management with colchicine was favored in most cases, followed by non-steroidal anti-inflammatory drugs (NSAIDs), and interventional therapy was only needed when patient developed cardiac tamponade. The majority of the reviewed studies reported either recovery or no continued clinical deterioration.The prevalence of COVID-19-related cardiac diseases is high, and pericarditis is a known extrapulmonary manifestation. However, pericardial effusion and cardiac tamponade are less prevalent and may require urgent intervention to prevent mortality. Pericarditis should be considered in patients with chest pain, ST elevation on ECG, a normal coronary angiogram, and COVID-19. We emphasize the importance of clinical examination, ECG, and echocardiogram for decision-making, and NSAIDs, colchicine, and corticosteroids are considered to be safe in the treatment of pericarditis/myopericarditis associated with COVID-19.

show abstract

Pericarditis secondary to COVID-19 infection in a kidney transplant recipient

Cited by 2 publications

References 9 publications

Pericarditis in patients with COVID-19: a systematic review

Pericarditis in patients with COVID-19: a systematic review

A Systematic Review of COVID-19 and Pericarditis

Contact Info

Product

Resources

About